title: [Brainstem metastasis from a prostate adenocarcinoma in the context of Muir-Torre syndrome].
abstract: BACKGROUND
  Muir-Torre syndrome is a genetic disease characterised by the association of sebaceous neoplasms with visceral neoplasms, mainly colorectal cancer and secondly urogenital tumours. Metastases from prostate tumours without systemic disease are rare in the brain and exceptional in the brainstem.
  
  
  METHODS
  We present a 48-year old male, with a single brainstem metastasis from a prostate adenocarcinoma, who had previously been diagnosed with Muir-Torre syndrome. Diagnostic stereotactic biopsy was performed.
  
  
  CONCLUSIONS
  Single metastasis from a prostate adenocarcinoma in the brainstem without systemic disease is exceptional. Due to the different diagnostic possibilities, biopsy should be performed in order to obtain a diagnosis, especially in the context of Muir-Torre syndrome.
authors.affiliation: Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España. Electronic address: gaorzaiz@unav.es.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Aldave
authors.forename: Eva
authors.initials: E
authors.lastname: Pay
authors.forename: Francisco
authors.initials: F
authors.lastname: Queipo
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Idoate
authors.forename: Jorge
authors.initials: J
authors.lastname: Guridi
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics / Q000556:secondary* / Q000628:therapy; D000236:Adenoma / Q000235:genetics; D000813:Anilides / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D020295:Brain Stem Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000556:secondary*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D055653:Muir-Torre Syndrome / Q000235:genetics; D051718:MutS Homolog 2 Protein / Q000172:deficiency / Q000235:genetics; D009154:Mutation; D009378:Neoplasms, Multiple Primary / Q000235:genetics; D038361:Neuronavigation / Q000379:methods; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000235:genetics; D012811:Sigmoid Neoplasms / Q000235:genetics; D043823:Taxoids / Q000008:administration & dosage; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D043823:Taxoids; D014105:Tosyl Compounds; D000077143:Docetaxel; C053541:bicalutamide; C497172:MSH2 protein, human; D051718:MutS Homolog 2 Protein